7 Best Value Picks for Investors: Pros

With the markets on a decline, investors need to put money into value plays, said Rob Hoxton, president and CEO of Hoxton Financial, and Robert Auer, portfolio manager at Auer Growth Fund.

“We look for fast-growing companies that are also very cheap,” Auer told CNBC.

In particular, Auer advised investors to look into the generic drug sector as it benefits from patents being removed from big pharmas. (Scroll down for his full list of picks.)

In the meantime, Hoxton said he is in favor of the housing space.

“If you look at what’s happened with housing, most of the pain’s probably been seen and we’re strengthening in some markets," he explained. "Look to companies that retail and manufacture stuff that the homeowners can use in the meantime, before the market recovers."

“And when the market does recover, then they’ll benefit from stronger housing and housing shortages.”

Auer Likes:


Endo Pharma

Rubicon Tech

Hoxton Likes:




Roche ADR

Scorecard—What They Said:

  • Auer's Previous Appearance on CNBC (Sept. 27, 2010)
  • Hoxton's Previous Appearance on CNBC (Dec. 23, 2010)

Other Market Views:

CNBC Data Pages:

CNBC Slideshows—FYI:



Auer owns shares of ENDP, RBCN and JPM in the Auer Growth Fund.

No immediate information was available for Hoxton or his firm.